Sage Therapeutics, Inc. (NASDAQ:SAGE) has been given an average rating of “Buy” by the sixteen ratings firms that are currently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation, ten have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $89.00.

A number of equities analysts recently commented on SAGE shares. BidaskClub downgraded Sage Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. BMO Capital Markets reiterated a “buy” rating and set a $82.00 price objective on shares of Sage Therapeutics in a research report on Friday, July 28th. Stifel Nicolaus reiterated a “buy” rating and set a $90.00 price objective on shares of Sage Therapeutics in a research report on Friday, July 14th. Canaccord Genuity set a $110.00 price objective on Sage Therapeutics and gave the stock a “buy” rating in a research report on Saturday, August 5th. Finally, Cowen and Company reiterated a “buy” rating and set a $100.00 price objective on shares of Sage Therapeutics in a research report on Friday, August 4th.

Sage Therapeutics (SAGE) opened at 62.36 on Friday. Sage Therapeutics has a 52-week low of $38.30 and a 52-week high of $90.80. The stock’s 50 day moving average price is $81.33 and its 200 day moving average price is $74.82. The company’s market cap is $2.33 billion.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.63) by ($0.25). During the same period in the previous year, the firm posted ($1.08) earnings per share. Analysts expect that Sage Therapeutics will post ($7.38) earnings per share for the current year.

Large investors have recently bought and sold shares of the business. State of Wisconsin Investment Board purchased a new stake in Sage Therapeutics in the second quarter valued at $1,991,000. Teacher Retirement System of Texas acquired a new stake in shares of Sage Therapeutics in the second quarter valued at $202,000. Schwab Charles Investment Management Inc. grew its stake in shares of Sage Therapeutics by 1.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 131,440 shares of the biopharmaceutical company’s stock valued at $9,342,000 after buying an additional 1,593 shares in the last quarter. Spark Investment Management LLC acquired a new stake in shares of Sage Therapeutics in the first quarter valued at $4,086,000. Finally, Rhumbline Advisers grew its stake in shares of Sage Therapeutics by 9.4% in the second quarter. Rhumbline Advisers now owns 41,138 shares of the biopharmaceutical company’s stock valued at $3,276,000 after buying an additional 3,551 shares in the last quarter.

WARNING: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/16/sage-therapeutics-inc-sage-receives-average-rating-of-buy-from-analysts-2.html.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.